Literature DB >> 26278328

Aberrant Placental Villus Expression of miR-486-3p and miR-3074-5p in Recurrent Miscarriage Patients and Uterine Expression of These MicroRNAs during Early Pregnancy in Mice.

Yan Gu1, Xuan Zhang, Qian Yang, Jianmei Wang, Yaping He, Zhaogui Sun, Huiqin Zhang, Jian Wang.   

Abstract

MicroRNAs (miRNAs) are critical regulators of gene expression; they have emerged as new players in the pathophysiology of reproductive disorders such as preeclampsia and recurrent miscarriage (RM). In this study, miRNA expression profiles were determined by deep sequencing analysis in placental villi obtained from women with RM and with gestational age-matched normal pregnancy (NP). A total of 69 miRNAs were found to be aberrantly expressed in RM. Five of these human (Homo sapiens) miRNAs (hsa-miRNAs), including hsa-miR-3074-5p, -486-3p, -1269b, -6765-3p and -144-3p, were validated by qRT-PCR in 12 RM and 10 NP placental villi. Hsa-miR-3074-5p expression was significantly higher, while hsa-miR-486-3p expression was significantly lower, in RM compared to NP. Subsequently, the expression of mouse (Mus musculus) miR-486-3p (mmu-miR-486-3p) and mmu-miR-3074-5p, which are identical to hsa-miR-486-3p and hsa-miR-3074-5p, respectively, were examined by qRT-PCR in the uterus during early pregnancy. Mmu-miR-486-3p expression was significantly increased during the peri-implantation period, and the levels were significantly higher at implantation than at non-implantation sites. In contrast, the expression of mmu-miR-3074-5p was markedly decreased at implantation compared to non-implantation sites. These data suggest that miR-486-3p and miR-3074-5p may be involved in embryo implantation and that their aberrant expression is associated with RM. Larger studies are warranted to follow up this pilot study.
© 2015 S. Karger AG, Basel.

Entities:  

Year:  2015        PMID: 26278328     DOI: 10.1159/000435879

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  7 in total

1.  Uterine Expression of NDRG4 Is Induced by Estrogen and Up-Regulated during Embryo Implantation Process in Mice.

Authors:  Qian Yang; Yan Gu; Xuan Zhang; Jian-Mei Wang; Ya-Ping He; Yan Shi; Zhao-Gui Sun; Hui-Juan Shi; Jian Wang
Journal:  PLoS One       Date:  2016-05-13       Impact factor: 3.240

2.  Circulating MicroRNA Profile as a Potential Predictive Biomarker for Early Diagnosis of Spontaneous Abortion in Patients With Subclinical Hypothyroidism.

Authors:  Yingying Zhou; Xinyi Wang; Yuanyuan Zhang; Tong Zhao; Zhongyan Shan; Weiping Teng
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-06       Impact factor: 5.555

3.  Association of the peripheral blood levels of circulating microRNAs with both recurrent miscarriage and the outcomes of embryo transfer in an in vitro fertilization process.

Authors:  Qian Yang; Wen-Wen Gu; Yan Gu; Na-Na Yan; Yan-Yan Mao; Xing-Xing Zhen; Jian-Mei Wang; Jing Yang; Hui-Juan Shi; Xuan Zhang; Jian Wang
Journal:  J Transl Med       Date:  2018-07-04       Impact factor: 5.531

4.  A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancer.

Authors:  Min Zhou; Tao Wu; Yuan Yuan; Shu-Juan Dong; Zhi-Ming Zhang; Yan Wang; Jing Wang
Journal:  J Ovarian Res       Date:  2022-05-06       Impact factor: 5.506

5.  Association of miR-34a-3p/5p, miR-141-3p/5p, and miR-24 in Decidual Natural Killer Cells with Unexplained Recurrent Spontaneous Abortion.

Authors:  Dandan Li; Jian Li
Journal:  Med Sci Monit       Date:  2016-03-21

Review 6.  Noncoding RNAs in Unexplained Recurrent Spontaneous Abortions and Their Diagnostic Potential.

Authors:  Ningyi Jia; Jian Li
Journal:  Dis Markers       Date:  2019-12-04       Impact factor: 3.434

7.  Trypanosoma cruzi and Toxoplasma gondii Induce a Differential MicroRNA Profile in Human Placental Explants.

Authors:  Lisvaneth Medina; Christian Castillo; Ana Liempi; Jesús Guerrero-Muñoz; Maura Rojas-Pirela; Juan Diego Maya; Humberto Prieto; Ulrike Kemmerling
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.